Table 3.
Follow-up on patients at 2 years clinical outcomes
| Clinical outcomes (n, %) | DM | No-DM | ||||
|---|---|---|---|---|---|---|
| G2‑DES N = 1862 |
BP‑DES N = 421 |
p | G2‑DES N = 4232 |
BP‑DES N = 1151 |
P | |
| MACE | 219 (11.8) | 60 (14.3) | 0.159 | 403 (9.5) | 129 (11.2) | 0.089 |
| All-cause death | 27 (1.5) | 6 (1.4) | 0.969 | 40 (0.9) | 16 (1.4) | 0.187 |
| Cardiac death | 16 (0.9) | 2 (0.5) | 0.554 | 25 (0.6) | 6 (0.5) | 0.782 |
| Non-fatal MI | 37 (2.0) | 15 (3.6) | 0.050 | 75 (1.8) | 17 (1.5) | 0.493 |
| ST | 20 (1.1) | 5 (1.2) | 0.797 | 32 (0.8) | 6 (0.5) | 0.399 |
| Revascularization | 145 (7.8) | 39 (9.3) | 0.315 | 279 (6.6) | 89 (7.7) | 0.174 |
| TVR | 81 (4.4) | 24 (5.7) | 0.232 | 136 (3.2) | 59 (5.1) | 0.002 |
| TLR | 66 (3.5) | 22 (5.2) | 0.106 | 92 (2.2) | 52 (4.5) | < 0.001 |
| Stroke | 26 (1.4) | 4 (1.0) | 0.468 | 51 (1.2) | 15 (1.3) | 0.789 |
| Bleeding | 124 (6.7) | 21 (5.0) | 0.204 | 310 (7.3) | 79 (6.9) | 0.592 |
| BARC 2_5 | 50 (2.7) | 8 (1.9) | 0.355 | 123 (2.9) | 31 (2.7) | 0.701 |
| BARC 3_5 | 8 (0.4) | 1 (0.2) | > 0.999 | 24 (0.6) | 4 (0.3) | 0.358 |
DM diabetes mellitus, G2-DES second generation drug-eluting stent, BP-DES biodegradable polymer drug-eluting stent, MACE major adverse cardiac events, MI myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, TLR target lesion revascularization, BARC Bleeding Academic Research Consortium definition